965 related articles for article (PubMed ID: 24352465)
41. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie.
Fischer M; Rülicke T; Raeber A; Sailer A; Moser M; Oesch B; Brandner S; Aguzzi A; Weissmann C
EMBO J; 1996 Mar; 15(6):1255-64. PubMed ID: 8635458
[TBL] [Abstract][Full Text] [Related]
42. Dissociation of infectivity from seeding ability in prions with alternate docking mechanism.
Miller MB; Geoghegan JC; Supattapone S
PLoS Pathog; 2011 Jul; 7(7):e1002128. PubMed ID: 21779169
[TBL] [Abstract][Full Text] [Related]
43. Insights into Mechanisms of Transmission and Pathogenesis from Transgenic Mouse Models of Prion Diseases.
Moreno JA; Telling GC
Methods Mol Biol; 2017; 1658():219-252. PubMed ID: 28861793
[TBL] [Abstract][Full Text] [Related]
44. Immunopurification of pathological prion protein aggregates.
Biasini E; Tapella L; Mantovani S; Stravalaci M; Gobbi M; Harris DA; Chiesa R
PLoS One; 2009 Nov; 4(11):e7816. PubMed ID: 19915706
[TBL] [Abstract][Full Text] [Related]
45. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
46. Genetic and infectious prion diseases.
Prusiner SB
Arch Neurol; 1993 Nov; 50(11):1129-53. PubMed ID: 8105771
[TBL] [Abstract][Full Text] [Related]
47. A new method for the characterization of strain-specific conformational stability of protease-sensitive and protease-resistant PrPSc.
Pirisinu L; Di Bari M; Marcon S; Vaccari G; D'Agostino C; Fazzi P; Esposito E; Galeno R; Langeveld J; Agrimi U; Nonno R
PLoS One; 2010 Sep; 5(9):e12723. PubMed ID: 20856860
[TBL] [Abstract][Full Text] [Related]
48. Recombinant human prion protein inhibits prion propagation in vitro.
Yuan J; Zhan YA; Abskharon R; Xiao X; Martinez MC; Zhou X; Kneale G; Mikol J; Lehmann S; Surewicz WK; Castilla J; Steyaert J; Zhang S; Kong Q; Petersen RB; Wohlkonig A; Zou WQ
Sci Rep; 2013 Oct; 3():2911. PubMed ID: 24105336
[TBL] [Abstract][Full Text] [Related]
49. Sheep scrapie susceptibility-linked polymorphisms do not modulate the initial binding of cellular to disease-associated prion protein prior to conversion.
Rigter A; Bossers A
J Gen Virol; 2005 Sep; 86(Pt 9):2627-2634. PubMed ID: 16099922
[TBL] [Abstract][Full Text] [Related]
50. The charge structure of helix 1 in the prion protein regulates conversion to pathogenic PrPSc.
Norstrom EM; Mastrianni JA
J Virol; 2006 Sep; 80(17):8521-9. PubMed ID: 16912302
[TBL] [Abstract][Full Text] [Related]
51. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
Katorcha E; Makarava N; Savtchenko R; D'Azzo A; Baskakov IV
PLoS Pathog; 2014 Sep; 10(9):e1004366. PubMed ID: 25211026
[TBL] [Abstract][Full Text] [Related]
52. Differential solubility of prions is associated in manifold phenotypes.
Kuczius T; Karch H; Groschup MH
Mol Cell Neurosci; 2009 Nov; 42(3):226-33. PubMed ID: 19607920
[TBL] [Abstract][Full Text] [Related]
53. Altered distribution, aggregation, and protease resistance of cellular prion protein following intracranial inoculation.
Ward A; Hollister JR; Choi YP; Race B; Williams K; Shoup DW; Moore RA; Priola SA
PLoS One; 2019; 14(7):e0219457. PubMed ID: 31291644
[TBL] [Abstract][Full Text] [Related]
54. Prion seeding activities of mouse scrapie strains with divergent PrPSc protease sensitivities and amyloid plaque content using RT-QuIC and eQuIC.
Vascellari S; Orrù CD; Hughson AG; King D; Barron R; Wilham JM; Baron GS; Race B; Pani A; Caughey B
PLoS One; 2012; 7(11):e48969. PubMed ID: 23139828
[TBL] [Abstract][Full Text] [Related]
55. Transmissible and genetic prion diseases share a common pathway of neurodegeneration.
Hegde RS; Tremblay P; Groth D; DeArmond SJ; Prusiner SB; Lingappa VR
Nature; 1999 Dec; 402(6763):822-6. PubMed ID: 10617204
[TBL] [Abstract][Full Text] [Related]
56. Amino acid sequence and prion strain specific effects on the in vitro and in vivo convertibility of ovine/murine and bovine/murine prion protein chimeras.
Kupfer L; Eiden M; Buschmann A; Groschup MH
Biochim Biophys Acta; 2007 Jun; 1772(6):704-13. PubMed ID: 17145171
[TBL] [Abstract][Full Text] [Related]
57. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
58. Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction.
Wang H; Tian C; Fan XY; Chen LN; Lv Y; Sun J; Zhao YJ; Zhang LB; Wang J; Shi Q; Gao C; Chen C; Shao QX; Dong XP
Int J Biochem Cell Biol; 2015 May; 62():24-35. PubMed ID: 25724737
[TBL] [Abstract][Full Text] [Related]
59. Identifying critical sites of PrP(c)-PrP(Sc) interaction in prion-infected cells by dominant-negative inhibition.
Taguchi Y; Schätzl HM
Prion; 2013; 7(6):452-6. PubMed ID: 24401595
[TBL] [Abstract][Full Text] [Related]
60. Selective processing and metabolism of disease-causing mutant prion proteins.
Ashok A; Hegde RS
PLoS Pathog; 2009 Jun; 5(6):e1000479. PubMed ID: 19543376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
